Analyst Scoreboard: 4 Ratings For Evolus
Portfolio Pulse from Benzinga Insights
Evolus (NASDAQ:EOLS) has received diverse analyst ratings over the past three months, with a majority being bullish. The average 12-month price target has increased by 4.6% to $22.75. Analysts have adjusted their ratings and price targets, reflecting positive sentiment. Evolus, a performance beauty company, has shown strong revenue growth but faces challenges with high debt and low ROE and ROA.
September 13, 2024 | 4:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evolus has received mostly bullish analyst ratings, with an average price target increase to $22.75. The company shows strong revenue growth but faces challenges with high debt and low ROE and ROA.
The majority of analysts have given bullish ratings, and the average price target has increased, indicating positive sentiment. However, financial challenges such as high debt and low ROE/ROA could impact future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100